BRAINLIFE.ORG





Topics


High-grade gliomas | Treatment | Clinical trials | Nivolumab






Home > Publications > Topics > High-grade gliomas > Treatment > Clinical trials > Nivolumab






Duerinck J, Lescrauwaet L, Dirven I, Del'haye J, Stevens L, Geeraerts X, Vaeyens F, Geens W, Brock S, Vanbinst AM, Everaert H, Caljon B, Bruneau M, Lebrun L, Salmon I, Kockx M, Tuyaerts S, Neyns B.
Intracranial administration of anti-PD-1 and anti-CTLA-4 immune checkpoint-blocking monoclonal antibodies in patients with recurrent high-grade glioma.
Neuro Oncol. 2024 Oct 16:noae177. doi: 10.1093/neuonc/noae177. PMID: 39406392. Interventional study. ˍ




Kesari S, Wojcinski A, Pabla S, Seager RJ, Gill JM, Carrillo JA, Wagle N, Park DJ, Nguyen M, Truong J, Takasumi Y, Chaiken L, Chang SC, Barkhoudarian G, Kelly DF, Juarez TM.
Pre-radiation Nivolumab plus ipilimumab in patients with newly diagnosed high-grade gliomas.
Oncoimmunology. 2024 Nov 21;13(1):2432728. doi: 10.1080/2162402X.2024.2432728. PMID: 39572979. Interventional study. ˍ